Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News BioDelivery Sciences International Inc. BDSI

BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.

Recent & Breaking News (NDAQ:BDSI)

BioDelivery Sciences International to Host ELYXYB(TM) Investor Day

GlobeNewswire September 30, 2021

BioDelivery Sciences International Completes Acquisition of ELYXYB(TM) for Acute Migraine Treatment in the U.S. and Canada

GlobeNewswire September 9, 2021

BioDelivery Sciences to Exhibit Three Scientific Posters Comparing BELBUCA® to Oxycodone at the PAINWeek 2021 Conference

GlobeNewswire September 7, 2021

BioDelivery Sciences to Participate in Upcoming Virtual Investor Conferences

GlobeNewswire September 3, 2021

AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors

GlobeNewswire August 16, 2021

Biotech Stocks on Investors' Radar -- Athersys, AVEO Pharma, BioDelivery Sciences, and BioLine Rx

PR Newswire October 4, 2017

BioDelivery Sciences to Present at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 2017 Healthcare Conference

PR Newswire September 19, 2017

BioDelivery Sciences Announces Granting of Market Authorization Transfer by Health Canada for BELBUCA® and Associated Milestone Payment

PR Newswire September 12, 2017

BioDelivery Sciences Presents Data on BELBUCA® (buprenorphine) Buccal Film at the PAINWeek 2017 Conference

PR Newswire September 7, 2017

BioDelivery Sciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

PR Newswire August 24, 2017

BioDelivery Sciences President and Chief Executive Officer Dr. Mark A. Sirgo to Retire at Year-End While Continuing as Vice Chairman

PR Newswire August 23, 2017

BioDelivery Sciences to Present Three Posters on BELBUCA® and BUNAVAIL® at PAINWeek 2017

PR Newswire August 17, 2017

BioDelivery Sciences Reports Second Quarter 2017 Financial Results and Provides Corporate Update

PR Newswire August 9, 2017

Investor Network: BioDelivery Sciences International, Inc. to Host Earnings Call

Accesswire August 9, 2017

Technical Reports on Biotech Equities -- BioDelivery Sciences, BioLine Rx, Benitec Biopharma, and Soligenix

PR Newswire August 1, 2017

BioDelivery Sciences Publishes Shareholder Letter with Mid-Year Corporate Update

PR Newswire July 31, 2017

BioDelivery Sciences to Host Conference Call and Webcast Reporting

PR Newswire July 28, 2017

BioDelivery Sciences Signs Exclusive Agreement With Purdue Pharma (Canada) for the Licensing and Distribution Rights of BELBUCA® in Canada

Canada NewsWire July 12, 2017

BioDelivery Sciences Announces Health Canada Approval of BELBUCA®

PR Newswire June 23, 2017

Mid-Afternoon Market Update: Crude Oil Down 3%; La-Z-Boy Shares Gain On Earnings Beat  June 21, 2017